Tagged with Pierre Fabre

France At the 13th annual meeting of French life sciences think tank, G5 Santé – which represents the leaders of eight major French health and life sciences companies, including bioMérieux, Sanofi, Ipsen, and Pierre Fabre – arguments were made for increasing efficiency in a healthcare system that is “on its last…

France In conversation at ESMO 2024, Pierre Fabre’s R&D Head Francesco Hofmann outlines some of the key data readouts for the company’s oncology portfolio from this year’s conference, how it is looking to expand its R&D portfolio via business development deals and biotech partnerships, and the spaces in which a mid-sized…

France With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination for international investments, France is looking to boost innovation, attracting the largest number of R&D centres in Europe in 2022,…

Morocco Pierre Fabre has been present in the Moroccan market for nearly 40 years. Pierre Behnam, the company’s director for Africa, Middle-East and Türkiye discusses its strategy for bringing innovation and targeted therapies to patients in Morocco.   I am confident that over time, with joint work between innovators and health…

France France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has demonstrated its willingness to take steps towards levelling its pricing barometers and in so doing tackle medicine shortages and build…

UAE French-headquartered Pierre Fabre has merged its dermo cosmetics and medical care arms under a single management team over the past four years; a strategy that has helped the firm to triple its profits in the Middle East. Naim Hanna outlines the company’s operational model and strategy in the region, how…

Italy The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who independently manage the budget for territorial pharmaceutical expenditure and evaluate regional access. According to many industry stakeholders, this lengthy process…

Italy Pierre Fabre Italy’s Charles-Henri Bodin highlights how the French firm’s offering has expanded far beyond its dermo-cosmetics heritage to today encompass a wide range of pharmaceuticals, including the key growth area of oncology. Bodin also outlines the importance of Italy – one of PF’s first international affiliates – to the…

France The latest news from French pharma, including AI-based biotech Owkin’s new status as a USD one billion-valued unicorn following fresh investment from Sanofi. Also included is another deal for Sanofi, this time in the form of a partnership with Chinese tech giant Baidu to use its algorithm for mRNA sequencing.…

Europe While 2020 may have seemed like the year the world stood still for many, the pharma industry went into overdrive, working around the clock to ensure security of supply as well as develop diagnostics, treatments, and vaccines for COVID-19. Recruitment also continued apace; here four recent country manager appointees share…

Global The top 10 most-read interviews on PharmaBoardroom in 2020 represents the broad geographic scope we have had in the past year. From Mexico to Morocco and Romania to Riyadh, these local insights help give a more well-rounded global picture of our industry today.   1. Bill Sibold, Executive VP, Sanofi…

Talent COVID-19 has necessitated enormous shifts in the way we live, work, and communicate with each other. Nowhere is this more apparent professionally than for those starting a new job. Here, we highlight four recent appointees to new roles in pharma companies across Europe and the USA and how they have…